{"id":11439,"date":"2025-07-26T18:57:15","date_gmt":"2025-07-26T16:57:15","guid":{"rendered":"https:\/\/valintermed.com\/?p=11439"},"modified":"2025-07-26T18:57:15","modified_gmt":"2025-07-26T16:57:15","slug":"her2-otritsatelnyy-rak-molochnoy-zhelezy","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/her2-breast-cancer\/","title":{"rendered":"HER2 negative breast cancer"},"content":{"rendered":"
<\/div>\n

HER2-negative breast cancer is considered one of the most common subtypes of breast cancer, characterized by the absence of overexpression of the human epidermal growth factor receptor 2 (HER2). This type of cancer is characterized by an aggressive course, but its deviation from HER2-positive cancer gives a number of differences in epidemiology, pathogenesis and treatment methods. HER2-negative cancer is often associated with higher levels of estrogen and progesterone, but not all patients require aggressive therapy, which makes correct diagnosis and an individualized approach to treatment important.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n